This review found that transient elastography appeared to be an important non-invasive method for the assessment of liver fibrosis, but further research is needed. Potential biases in the review process and lack of clarity of study design and quality means that the results of the review should be interpreted with caution ; the reliability of the authors' conclusion is unclear.
Study selection
Primary studies that assessed the accuracy of transient elastography (index test) compared with liver biopsy (reference or gold standard) for the diagnosis of liver fibrosis were eligible for inclusion. Studies had to provide detailed descriptions of the patients. Eligible studies were required to report optimal cut-offs or cut-offs in stiffness values, and/or diagnostic accuracy data suitable for meta-analysis (sensitivity, specificity, positive and negative predictive values, and area under receiver operating characteristic curves). Studies that compared transient elastography with other non-invasive serum markers were also included.
All the included studies were conducted in large or regional hospitals. The enrolled patients presented with mixed aetiologies, including hepatitis B virus, hepatitis C virus and hepatitis C post-orthotopic liver transplantation, HIV, and non-alcoholic fatty liver disease. The mean body mass index of included patients ranged from 21 to over 30kg/m 2; their mean age ranged from 42 to 63 years; most were men. Percutaneous liver biopsies were performed in most studies; transjugular liver biopsies were performed in some studies. Most of the studies correlated liver stiffness measurements and fibrosis staging by histopathology according to the five-step METAVIR scoring system (ranging from F0 to F4). Significant fibrosis corresponded to cut-off values (in kilopascals) of up to F2; liver cirrhosis corresponded to a cut-off value of F4.
